Get started
Author

Stefan Svensson Gelius

Observed names: Gelius, Stefan Svensson, Stefan Svensson. Gelius
ORCID: 0000-0003-1777-2755
Observed ORCID: 0000-0003-1777-2755
OpenAlex ID: A5069801287
Exploring the therapeutic potential of modern and ancestral phenylalanine/tyrosine ammonia-lyases as supplementary treatment of hereditary tyrosinemia
2020 · Natalie M. Hendrikse, Albin Holmberg Larsson, et al. · Scientific Reports · 36
PDF
Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice
2019 · Susanne Gustavsson, Elisabet Ohlin Sjöström, et al. · Molecular Genetics and Metabolism Reports · 21
PDF
CCL2 mediates anti-fibrotic effects in human fibroblasts independently of CCR2
2014 · Christina Kalderén, Charlotte Stadler, et al. · International Immunopharmacology · 19
Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells
2023 · Kim Anh Giang, Thorstein Boxaspen, et al. · New Biotechnology · 17
PDF
An improved barium-rhodizonate method for determination of sulfate ion in biological fluids
2020 · Chao Su, Stefan Svensson Gelius · Analytical Biochemistry · 15
Aminopeptidases in Cancer, Biology and Prospects for Pharmacological Intervention
2022 · Fredrik Lehmann, Sarah A. Holstein, et al. · Current Cancer Drug Targets · 14
Robust LC–MS/MS Methods for Analysis of Heparan Sulfate Levels in CSF and Brain for Application in Studies of MPS IIIA
2019 · Åsa Makower, Erik Arnelöf, et al. · Bioanalysis · 10
A truncated analogue of CCL2 mediates anti-fibrotic effects on murine fibroblasts independently of CCR2
2011 · Christina Kalderén, Margareta Forsgren, et al. · Biochemical Pharmacology · 9
Ancestral lysosomal enzymes with increased activity harbor therapeutic potential for treatment of Hunter syndrome
2021 · Natalie M. Hendrikse, Anna Sandegren, et al. · iScience · 8
PDF
A rapid intracellular enrichment of alkylating payload is essential for melphalan flufenamide potency and mechanism of action
2023 · Ulrica Westermark, Yumei Diao, et al. · Biochemical and Biophysical Research Communications · 6
Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study
2022 · Paul Harmatz, Joseph Muenzer, et al. · Molecular Genetics and Metabolism · 6
PDF
Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
2025 · Klara Acs, Juho J. Miettinen, et al. · Experimental Hematology and Oncology · 4
PDF
Ex vivo expanded adaptive NK cells in combination with a bispecific NK cell engager targeting BCMA for synergistic control of multiple myeloma
2025 · Thorstein Boxaspen, Hannah Cuthbertson Husbyn, et al. · Blood · 3
PDF
An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma
2025 · Kim Anh Giang, Johan Nilvebrant, et al. · International Journal of Molecular Sciences · 3
PDF
Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Towards Multiple Myeloma
2022 · Kim Anh Giang, Mizuha Kanaya, et al. · Blood · 3
Efficacy of the Peptide Drug Conjugates Melflufen and OPDC3 in Venetoclax Resistant Acute Myeloid Leukemia
2024 · Romika Kumari, Juho J. Miettinen, et al. · Blood · 2
Abstract 1598: Preclinical efficacy of a bispecific NK cell engager studied using a humanized multiple myeloma mouse model
2026 · Mari I. Suominen, Katja M. Fagerlund, et al. · Cancer Research
Abstract B092: A preclinical ex vivo model for glioblastoma captures patient heterogeneity in drug response
2025 · Ezgi Kaya Aksoy, Ulrica Westermark, et al. · Molecular Cancer Therapeutics
Abstract 1282: Development of a humanized multiple myeloma mouse model using bone-derived MM.1S cells
2025 · Mari I. Suominen, Katja M. Fagerlund, et al. · Cancer Research
Additional file 8 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
2025 · Acs, Klara, Miettinen, Juho J., et al. · Figshare
Additional file 3 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
2025 · Acs, Klara, Miettinen, Juho J., et al. · Figshare
Additional file 1 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
2025 · Acs, Klara, Miettinen, Juho J., et al. · Figshare
Additional file 10 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
2025 · Acs, Klara, Miettinen, Juho J., et al. · Figshare
Additional file 2 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
2025 · Acs, Klara, Miettinen, Juho J., et al. · Figshare
Additional file 5 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
2025 · Acs, Klara, Miettinen, Juho J., et al. · Figshare
Works count: 38
Citation count: 176
H-index: 8
I10-index: 7
Year
Topic
Type